Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2019 Aug 8;39(10):2145–2156. doi: 10.1161/ATVBAHA.119.312723

Figure 5: Association of apoC-III glycoforms with TG levels before and after volanesorsen treatment.

Figure 5:

(A) The relative abundance of apoC-III1 was significantly correlated with TG levels (r= 0.54, p = 0.0009). (B) In contrast, the relative abundance of apoC-III2 was inversely associated with TG levels (r = −0.36, p = 0.03). (C) The ratio of apoC-III2/apoC-III1 was inversely associated with TG levels (r = −0.41, p = 0.016). At 85 days after treatment, (D) change in relative abundance of apoC-III1 was strongly correlated with change in TG levels (r = 0.63, p = 0.006). (E) Change in relative abundance of apoC-III2 was inversely correlated with change in TG levels (r = −0.55, p = 0.02). (F) Change in apoC-III2/apoC-III1 ratio was inversely associated with change in TG levels (r = −0.54, p = 0.02).